ArticleJournal of endocrinological investigation2026
Long-term endocrine and testicular outcomes in male survivors of childhood acute lymphoblastic leukemia.
Article in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimSurvivors of childhood acute lymphoblastic leukemia (ALL) are at risk for long-term endocrine and gonadal dysfunction. While several studies have explored these risks in heterogeneous cancer survivor groups, data specific to ALL survivors remain limited. Herein, we aimed to evaluate late endocrine and gonadal effects in a homogeneous cohort of male childhood ALL survivors classified by risk groups, and to assess the predictive value of serum follicle-stimulating hormone (FSH) and anti-Müllerian hormone (AMH) levels for semen analysis outcomes.
methodsThis cohort study included male survivors of childhood ALL treated between 2000 and 2020, classified as standard, intermediate, or high risk. Endocrine parameters, reproductive hormones, and semen analyses were evaluated.
resultsFifty-four survivors (mean age 17.5 ± 5.9 years) were included. Endocrine disorders were present in 40.7%, with obesity in 9.4%. Semen analysis (n = 33) revealed abnormal findings in 42.4% and azoospermia in 24.2%. The prevalence of gonadal dysfunction increased progressively from standard to high-risk groups. FSH thresholds of 3.55 mIU/mL was predictive of abnormal semen parameters (AUC: 0.88). AMH showed no predictive value for semen outcomes.
conclusionsThis is the first study to evaluate gonadal outcomes through semen analysis in a homogeneous cohort of childhood ALL survivors stratified by risk group. Our findings support the use of FSH as a predictive marker of impaired spermatogenesis, while AMH appears to have no predictive value. The study also highlights the need for early reproductive counseling and consideration of fertility preservation strategies, especially in high-risk patients.
Indexed as
Identifiers
41511747What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.